| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Endocrinology, Vol 8, 1262-1277, Copyright © 1994 by Endocrine Society
ARTICLES |
TN Collingwood, M Adams, Y Tone and VK Chatterjee
Department of Medicine, University of Cambridge, Level 5 Addenbrooke's Hospital, United Kingdom.
Resistance to thyroid hormone (RTH) is usually dominantly inherited and characterized by elevated thyroid hormone levels, impaired feedback inhibition of pituitary TSH production, and variable hormonal responsiveness in peripheral tissues. We have identified 20 different mutations in the thyroid hormone beta-receptor (TR beta) gene in RTH and assayed mutant receptor properties using the TSH alpha subunit gene promoter or promoters containing three different types of positive thyroid response element (TRE). Dominant negative inhibition of wild type TR beta action by mutant receptors was also tested. The mutant receptors exhibited differing transcriptional inhibitory properties and dominant negative potential with the TSH alpha promoter that correlated with their impaired hormone binding, whereas transactivation and dominant negative effects with promoters containing positive TREs varied depending on their configuration. Heterodimeric mutant receptor- retinoid X receptor (RXR) interactions, either in cultured cells or as TRE-bound complexes in gel retardation assays, were uniformly preserved, whereas homodimeric receptor interactions could not be detected in vivo, and in vitro homodimer formation on TREs was variably reduced or absent for some mutant proteins. We correlate these findings with the distribution of receptor mutations that cluster in two areas within the hormone binding domain outside putative dimerization regions and show that artificial mutations that impaired heterodimerization abrogated dominant negative activity. Therefore, we suggest that the dominant negative effect of mutant receptors in the pituitary-thyroid axis generates the characteristic biochemical abnormality of RTH and that variable resistance in other tissues may be due to response element-dependent differences in their dominant negative potential.
This article has been cited by other articles:
![]() |
N K Agrawal, R Goyal, A Rastogi, D Naik, and S K Singh Thyroid hormone resistance Postgrad. Med. J., September 1, 2008; 84(995): 473 - 477. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ludtke, J. Buettner, W. Wu, A. Muchir, A. Schroeter, S. Zinn-Justin, S. Spuler, H. H.-J. Schmidt, and H. J. Worman Peroxisome Proliferator-Activated Receptor-{gamma} C190S Mutation Causes Partial Lipodystrophy J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2248 - 2255. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Jeninga, O. van Beekum, A. D. J. van Dijk, N. Hamers, B. I. Hendriks-Stegeman, A. M. J. J. Bonvin, R. Berger, and E. Kalkhoven Impaired Peroxisome Proliferator-Activated Receptor {gamma} Function through Mutation of a Conserved Salt Bridge (R425C) in Familial Partial Lipodystrophy Mol. Endocrinol., May 1, 2007; 21(5): 1049 - 1065. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Baris, A. E. Arisoy, A. Smith, M. Agostini, C. S. Mitchell, S. M. Park, A. M. Halefoglu, E. Zengin, V. K. Chatterjee, and E. Battaloglu A Novel Missense Mutation in Human TTF-2 (FKHL15) Gene Associated with Congenital Hypothyroidism But Not Athyreosis J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4183 - 4187. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Wu, R. N. Cohen, E. Simsek, D. A. Senses, N. E. Yar, H. Grasberger, J. Noel, S. Refetoff, and R. E. Weiss A Novel Thyroid Hormone Receptor-{beta} Mutation That Fails to Bind Nuclear Receptor Corepressor in a Patient as an Apparent Cause of Severe, Predominantly Pituitary Resistance to Thyroid Hormone J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1887 - 1895. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Togashi, P. Nguyen, R. Fletterick, J. D. Baxter, and P. Webb Rearrangements in Thyroid Hormone Receptor Charge Clusters That Stabilize Bound 3,5',5-Triiodo-L-thyronine and Inhibit Homodimer Formation J. Biol. Chem., July 8, 2005; 280(27): 25665 - 25673. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wan, B. Farboud, and M. L. Privalsky Pituitary Resistance to Thyroid Hormone Syndrome Is Associated with T3 Receptor Mutants that Selectively Impair {beta}2 Isoform Function Mol. Endocrinol., June 1, 2005; 19(6): 1529 - 1542. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Semple, A. Meirhaeghe, A. J. Vidal-Puig, J. W. R. Schwabe, D. Wiggins, G. F. Gibbons, M. Gurnell, V. K. K. Chatterjee, and S. O'Rahilly A Dominant Negative Human Peroxisome Proliferator-Activated Receptor (PPAR){alpha} Is a Constitutive Transcriptional Corepressor and Inhibits Signaling through All PPAR Isoforms Endocrinology, April 1, 2005; 146(4): 1871 - 1882. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Furumoto, H. Ying, G. V. R. Chandramouli, L. Zhao, R. L. Walker, P. S. Meltzer, M. C. Willingham, and S.-Y. Cheng An Unliganded Thyroid Hormone {beta} Receptor Activates the Cyclin D1/Cyclin-Dependent Kinase/Retinoblastoma/E2F Pathway and Induces Pituitary Tumorigenesis Mol. Cell. Biol., January 1, 2005; 25(1): 124 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Agostini, M. Gurnell, D. B. Savage, E. M. Wood, A. G. Smith, O. Rajanayagam, K. T. Garnes, S. H. Levinson, H. E. Xu, J. W. R. Schwabe, et al. Tyrosine Agonists Reverse the Molecular Defects Associated with Dominant-Negative Mutations in Human Peroxisome Proliferator-Activated Receptor {gamma} Endocrinology, April 1, 2004; 145(4): 1527 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Huber, B. Sandler, B. L. West, S. T. Cunha Lima, H. T. Nguyen, J. W. Apriletti, J. D. Baxter, and R. J. Fletterick Two Resistance to Thyroid Hormone Mutants with Impaired Hormone Binding Mol. Endocrinol., April 1, 2003; 17(4): 643 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. H. Coulthard, S. Matsuda, and D. M. Heery An Extended LXXLL Motif Sequence Determines the Nuclear Receptor Binding Specificity of TRAP220 J. Biol. Chem., March 21, 2003; 278(13): 10942 - 10951. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Huber, M. Desclozeaux, B. L. West, S. T. Cunha-Lima, H. T. Nguyen, J. D. Baxter, H. A. Ingraham, and R. J. Fletterick Thyroid Hormone Receptor-{beta} Mutations Conferring Hormone Resistance and Reduced Corepressor Release Exhibit Decreased Stability in the N-Terminal Ligand-Binding Domain Mol. Endocrinol., January 1, 2003; 17(1): 107 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Castanet, S.-M. Park, A. Smith, M. Bost, J. Leger, S. Lyonnet, A. Pelet, P. Czernichow, K. Chatterjee, and M. Polak A novel loss-of-function mutation in TTF-2 is associated with congenital hypothyroidism, thyroid agenesis and cleft palate Hum. Mol. Genet., August 15, 2002; 11(17): 2051 - 2059. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Kahaly, C. H. Matthews, S. Mohr-Kahaly, C. A. Richards, and V. K. K. Chatterjee Cardiac Involvement in Thyroid Hormone Resistance J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 204 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ercan-Fang, H. L. Schwartz, C. N. Mariash, and J. H. Oppenheimer Quantitative Assessment of Pituitary Resistance to Thyroid Hormone from Plots of the Logarithm of Thyrotropin Versus Serum Free Thyroxine Index J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2299 - 2303. [Abstract] [Full Text] |
||||
![]() |
M. Gurnell, J. M. Wentworth, M. Agostini, M. Adams, T. N. Collingwood, C. Provenzano, P. O. Browne, O. Rajanayagam, T. P. Burris, J. W. Schwabe, et al. A Dominant-negative Peroxisome Proliferator-activated Receptor gamma (PPARgamma ) Mutant Is a Constitutive Repressor and Inhibits PPARgamma -mediated Adipogenesis J. Biol. Chem., February 25, 2000; 275(8): 5754 - 5759. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gurnell, O. Rajanayagam, M. Agostini, R. J. D. Clifton-Bligh, T. Wang, P. M. J. Zelissen, F. van der Horst, A. v. d. Wiel, E. Macchia, A. Pinchera, et al. Three Novel Mutations at Serine 314 in the Thyroid Hormone {beta} Receptor Differentially Impair Ligand Binding in the Syndrome of Resistance to Thyroid Hormone Endocrinology, December 1, 1999; 140(12): 5901 - 5906. [Abstract] [Full Text] |
||||
![]() |
J. Pohlenz, R. E. Weiss, P. E. Macchia, S. Pannain, I. T. Lau, H. Ho, and S. Refetoff Five New Families with Resistance to Thyroid Hormone not Caused by Mutations in the Thyroid Hormone Receptor {beta} Gene J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3919 - 3928. [Abstract] [Full Text] |
||||
![]() |
C. Asteria, O. Rajanayagam, T. N. Collingwood, L. Persani, R. Romoli, D. Mannavola, P. Zamperini, F. Buzi, F. Ciralli, V. K. K. Chatterjee, et al. Prenatal Diagnosis of Thyroid Hormone Resistance J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 405 - 410. [Abstract] [Full Text] |
||||
![]() |
T. Tagami, W.-X. Gu, P. T. Peairs, B. L. West, and J. L. Jameson A Novel Natural Mutation in the Thyroid Hormone Receptor Defines a Dual Functional Domain That Exchanges Nuclear Receptor Corepressors and Coactivators Mol. Endocrinol., December 1, 1998; 12(12): 1888 - 1902. [Abstract] [Full Text] |
||||
![]() |
R. N. Cohen, F. E. Wondisford, and A. N. Hollenberg Two Separate NCoR (Nuclear Receptor Corepressor) Interaction Domains Mediate Corepressor Action on Thyroid Hormone Response Elements Mol. Endocrinol., October 1, 1998; 12(10): 1567 - 1581. [Abstract] [Full Text] |
||||
![]() |
L. Persani, S. Borgato, R. Romoli, C. Asteria, A. Pizzocaro, and P. Beck-Peccoz Changes in the Degree of Sialylation of Carbohydrate Chains Modify the Biological Properties of Circulating Thyrotropin Isoforms in Various Physiological and Pathological States J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2486 - 2492. [Abstract] [Full Text] |
||||
![]() |
R. J. Clifton-Bligh, F. de Zegher, R. L. Wagner, T. N. Collingwood, I. Francois, M. Van Helvoirt, R. J. Fletterick, and V. K. K. Chatterjee A Novel TR{beta} Mutation (R383H) in Resistance to Thyroid Hormone Syndrome Predominantly Impairs Corepressor Release and Negative Transcriptional Regulation Mol. Endocrinol., May 1, 1998; 12(5): 609 - 621. [Abstract] [Full Text] |
||||
![]() |
T. Tagami, P. Kopp, W. Johnson, O. K. Arseven, and J. L. Jameson The Thyroid Hormone Receptor Variant {alpha}2 Is a Weak Antagonist because It Is Deficient in Interactions with Nuclear Receptor Corepressors Endocrinology, May 1, 1998; 139(5): 2535 - 2544. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tagami and J. L. Jameson Nuclear Corepressors Enhance the Dominant Negative Activity of Mutant Receptors That Cause Resistance to Thyroid Hormone Endocrinology, February 1, 1998; 139(2): 640 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. N. Collingwood, A. Butler, Y. Tone, R. J. Clifton-Bligh, M. G. Parker, and V. K. K. Chatterjee Thyroid Hormone-mediated Enhancement of Heterodimer Formation between Thyroid Hormone Receptor beta and Retinoid X Receptor J. Biol. Chem., May 16, 1997; 272(20): 13060 - 13065. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Yoh, V. K. K. Chatterjee, and M. L. Privalsky Thyroid Hormone Resistance Syndrome Manifests as an Aberrant Interaction between Mutant T3 Receptors and Transcriptional Corepressors Mol. Endocrinol., April 1, 1997; 11(4): 470 - 480. [Abstract] [Full Text] |
||||
![]() |
M. Behr, D. B. Ramsden, and U. Loos Deoxyribonucleic Acid Binding and Transcriptional Silencing by a Truncated c-erbA{beta}1 Thyroid Hormone Receptor Identified in a Severely Retarded Patient with Resistance to Thyroid Hormone J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1081 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. N. Collingwood, O. Rajanayagam, M. Adams, R. Wagner, V. Cavailles, E. Kalkhoven, C. Matthews, E. Nystrom, K. Stenlof, G. Lindstedt, et al. A natural transactivation mutation in the thyroid hormone beta receptor: Impaired interaction with putative transcriptional mediators PNAS, January 7, 1997; 94(1): 248 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Safer, M. F. Langlois, R. Cohen, T. Monden, D. John-Hope, J. Madura, A. N. Hollenberg, and F. E. Wondisford Isoform Variable Action among Thyroid Hormone Receptor Mutants Provides Insight into Pituitary Resistance to Thyroid Hormone Mol. Endocrinol., January 1, 1997; 11(1): 16 - 26. [Abstract] [Full Text] |
||||
![]() |
Y.-Z. Yang, M. Burgos-Trinidad, Y. Wu, and R. J. Koenig Thyroid Hormone Receptor Variant alpha 2. ROLE OF THE NINTH HEPTAD IN DNA BINDING, HETERODIMERIZATION WITH RETINOID X RECEPTORS, AND DOMINANT NEGATIVE ACTIVITY J. Biol. Chem., November 8, 1996; 271(45): 28235 - 28242. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Hollenberg, T. Monden, and F. E. Wondisford Ligand-independent and -dependent Functions of Thyroid Hormone Receptor Isoforms Depend upon Their Distinct Amino Termini J. Biol. Chem., June 16, 1995; 270(24): 14274 - 14280. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. N. Collingwood, F. D. Urnov, V. K. K. Chatterjee, and A. P. Wolffe Chromatin Remodeling by the Thyroid Hormone Receptor in Regulation of the Thyroid-stimulating Hormone alpha -Subunit Promoter J. Biol. Chem., August 31, 2001; 276(36): 34227 - 34234. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |